FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242494536> ?p ?o ?g. }

• W4242494536 endingPage "5063" @default.
• W4242494536 startingPage "5063" @default.
• W4242494536 abstract "5063 Background: Topotecan 1.5 mg/m2 on days 1 through 5 of a 21-day cycle is an established chemotherapeutic regimen for recurrent ovarian cancer. However, noncumulative myelosuppression has limited topotecan's use in some patients (pts). Topotecan on a weekly schedule has been reported to be active in recurrent ovarian cancer pts with significantly reduced hematologic toxicity. The aim of this trial is to evaluate the safety and antitumor activity of weekly topotecan in pts with platinum-sensitive recurrent ovarian and peritoneal carcinoma. Methods: A prospective multi-institutional study began in July 2002 and is ongoing. Pts were required to have recurrent platinum-sensitive disease and no more than 2 prior treatment regimens. Topotecan was given at a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day cycle and escalated to 5 mg/m2 if well tolerated. Results: To date, 21 pts, 18 with ovarian and 3 with peritoneal carcinoma, have been enrolled. Fifteen are evaluable for toxicity and response. Four have just enrolled, 1 pt died before tumor reassessment, and 1 pt received only 1 cycle of therapy because of unrecovered blood counts. At study entry, the median age was 65 years (range, 43 to 82), median performance status was 0, and median number of prior regimens was 1. Pts received a median of 2 (range, 1 to 8) courses of topotecan. The overall response rate was 20% (3/15, all partial responses). An additional 6 (40%) pts had stable disease. Mean time to progression for responders and pts with stable disease was 26.4 (range, 25.6 to 26.8) and 16.6 (range, 10.7 to 30.7) weeks, respectively. Grade 4 neutropenia and anemia occurred in 2 pts (13.3%) and 1 pt (6.7%), respectively. No pts had grade 4 thrombocytopenia or neutropenic fever. G-CSF was used in 1 pt (6.7%) and erythropoietin was used in 6 pts (40%). Conclusions: Weekly topotecan in this setting is active with significant reductions in hematologic toxicity. Future studies using weekly topotecan in combination with other chemotherapeutic agents seem feasible given the low levels of hematologic toxicity observed in our trial. Further studies are being conducted to confirm these preliminary results. No significant financial relationships to disclose." @default.
• W4242494536 created "2022-05-12" @default.
• W4242494536 creator A5002713489 @default.
• W4242494536 creator A5026046767 @default.
• W4242494536 creator A5029359855 @default.
• W4242494536 creator A5032869739 @default.
• W4242494536 creator A5082256004 @default.
• W4242494536 date "2004-07-15" @default.
• W4242494536 modified "2023-09-24" @default.
• W4242494536 title "A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma" @default.
• W4242494536 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.5063" @default.
• W4242494536 hasPublicationYear "2004" @default.
• W4242494536 type Work @default.
• W4242494536 citedByCount "1" @default.
• W4242494536 crossrefType "journal-article" @default.
• W4242494536 hasAuthorship W4242494536A5002713489 @default.
• W4242494536 hasAuthorship W4242494536A5026046767 @default.
• W4242494536 hasAuthorship W4242494536A5029359855 @default.
• W4242494536 hasAuthorship W4242494536A5032869739 @default.
• W4242494536 hasAuthorship W4242494536A5082256004 @default.
• W4242494536 hasConcept C121608353 @default.
• W4242494536 hasConcept C126322002 @default.
• W4242494536 hasConcept C143998085 @default.
• W4242494536 hasConcept C2776694085 @default.
• W4242494536 hasConcept C2777546739 @default.
• W4242494536 hasConcept C2780427987 @default.
• W4242494536 hasConcept C2781209748 @default.
• W4242494536 hasConcept C3019054536 @default.
• W4242494536 hasConcept C71924100 @default.
• W4242494536 hasConceptScore W4242494536C121608353 @default.
• W4242494536 hasConceptScore W4242494536C126322002 @default.
• W4242494536 hasConceptScore W4242494536C143998085 @default.
• W4242494536 hasConceptScore W4242494536C2776694085 @default.
• W4242494536 hasConceptScore W4242494536C2777546739 @default.
• W4242494536 hasConceptScore W4242494536C2780427987 @default.
• W4242494536 hasConceptScore W4242494536C2781209748 @default.
• W4242494536 hasConceptScore W4242494536C3019054536 @default.
• W4242494536 hasConceptScore W4242494536C71924100 @default.
• W4242494536 hasIssue "14_suppl" @default.
• W4242494536 hasLocation W42424945361 @default.
• W4242494536 hasOpenAccess W4242494536 @default.
• W4242494536 hasPrimaryLocation W42424945361 @default.
• W4242494536 hasRelatedWork W1972483602 @default.
• W4242494536 hasRelatedWork W2073197076 @default.
• W4242494536 hasRelatedWork W2124273755 @default.
• W4242494536 hasRelatedWork W2298378430 @default.
• W4242494536 hasRelatedWork W2466209479 @default.
• W4242494536 hasRelatedWork W2526419534 @default.
• W4242494536 hasRelatedWork W2589558779 @default.
• W4242494536 hasRelatedWork W2604112126 @default.
• W4242494536 hasRelatedWork W3088178260 @default.
• W4242494536 hasRelatedWork W3155136893 @default.
• W4242494536 hasVolume "22" @default.
• W4242494536 isParatext "false" @default.
• W4242494536 isRetracted "false" @default.
• W4242494536 workType "article" @default.